

Financial Year End	31/03/2013
Reporting Period Ending	30/09/2012
Reporting Quarter	2Q-2013

**MALAYSIA EQUITY
GENETEC TECHNOLOGY BHD**

Recommendation	HOLD
Target Price (MYR)	0.20
Current Price (MYR)	0.17

Industry Group	Computers
Industry Sub Group	Computers-Integrated Sys

Key Company Statistics	
Bloomberg Ticker	GENE MK
Bursa Stock Code	0104
Issued Capital (mn shares)	351.7
Market Capitalisation (MYR mn)	59.8
52 week High (MYR)	0.26
52 week Low (MYR)	0.17
Average Volume (3 month) '000	11.5
1 Yr Return (%)	-17.1

Major Shareholders (%)	
Atis Corporation Bhd	27.4
Tan Moon Teik	23.2
Chin Kem Weng	15.5


FTSE-BURSA INDEX MEMBERSHIP

FBM KLCI	FBM 70	FBM EMAS	FBM HIJRAH
No	No	No	No

REPORT INDEX

Contents	Page
Recommendation, Company Profile, Metrics	1
Quarterly Results, Competitor's Metrics	2
P&L, Balance Sheet, Per Share Data	3
7 Year Sales, Net Profit, Price, P-BV charts	4
Recent Co. News, Recommendation Record	5
Analyst's Disclosure, Contact Details	6

SHARE PRICE LAST 12 MONTHS (MYR)



RESULTS REPORT

YTD 2Q FY13 revenue increased by 15.0% vs YTD 2Q FY12, however operating profits decreased by 50.2% over the same period as higher operating costs in the US crimped group margins. Looking ahead the next few quarters, operating margins are likely to range between 1-5% due to challenging conditions in the US. Though we may later raise our target price higher, we are still mindful of softening conditions in Europe and China. While GTB is not directly exposed to these economies, demand remains soft for hard drives and may even decline further as the shift away from PCs to tablets and smart phones continues.

INVESTMENT RISKS

Risks to our recommendation and target price include: i) softness in the demand for laptops and desktop computers, ii) a higher level of interest rates, iii) a renewed slowdown in the general level of economic activity in Malaysia or among its major trading partners: Singapore, China and the US.

RECOMMENDATION

We maintain our HOLD recommendation on Genetec Technology Bhd with a fair value estimate of MYR 0.20. Whilst GTB's shares are trading at the low end of its 5-year valuation band, average ROE is likely to remain in the neighbourhood of 3-4%. Earnings multiples stand on 19.8x FY Mar 13 profits, whilst P-BV is standing on 0.8x FY Mar 13 book value.

Net margins at GTB are likely to remain in the range of 1-2% over the next few quarters as costs remain elevated and HDD demand remains sluggish. Though HDD demand remains tepid in aggregate, Western Digital Corp's ("WDC") global market share has risen from 30% to 45%, which may benefit GTB down the road. We also note that GTB's recent acquisitions have added considerably to debt. In addition, profits from the US acquisition remain elusive. It may take two to three quarters before US operations make appreciable additions to total profits.

COMPANY PROFILE

Genetec Technology Bhd ("GTB") is mainly involved in the design and sales of industrial automation equipment. Prior to their latest acquisitions, the Hard Disk Drive ("HDD") segment accounted for approximately 90% of total turnover. Recent corporate exercises have more than doubled GTB's revenue and profits and will give them additional capacity to meet new orders from WDC. The company was formed in 1997 and converted to a public limited company in 2004, prior to listing in 2005.

ANNUAL RESULTS AND METRICS (MYR mn)

FY Mar	2011	2012	2013F	2014F
Revenue	123.0	155.4	171.6	186.6
Revenue g (%)	134.3	26.3	10.4	8.7
Net Profit	12.4	4.0	3.1	2.8
Net Profit g (%)	181.5	-67.4	-23.0	-10.4
Dividends	0.0	3.5	1.0	2.0
Owners' Equity	72.9	72.9	75.2	76.0
Total Liabilities	45.4	86.8	107.1	111.8
Debt/Equity (%)	62.2	119.1	142.5	147.1
EPS (sen)	3.5	1.2	0.9	0.8
P-S (x)	0.7	0.5	0.3	0.3
P-E (x)	7.2	18.7	19.2	21.4
P-BV (x)	1.2	1.0	0.8	0.8
ROE %	17.0	5.6	4.1	3.7

MALAYSIA EQUITY
GENETEC TECHNOLOGY BHD

QUARTERLY RESULTS TABLE (All figures in MYR mn unless otherwise indicated)

FY Mar	2Q-13	2Q-12	Q-o-Q %chg	YTD FY13	YTD FY12	Y-o-Y %chg
Revenue	43.8	39.9	9.9	91.3	79.4	15.0
Operating Profit	0.9	3.2	-70.4	2.8	5.6	-50.2
Other Income	0.1	0.1	-15.0	0.1	0.1	-51.1
Share of Associates	0.0	0.0	na	0.0	0.0	na
Depreciation/Amort'n	-0.2	0.0	na	-0.4	-0.3	11.8
Finance Costs	-0.8	-0.8	4.3	-1.6	-1.3	22.1
Pre Tax Profit	1.7	1.9	-8.3	2.4	3.9	-39.4
Tax	0.0	0.0	na	-0.2	-0.6	na
Minority Interest	-0.1	0.6	na	-0.2	0.4	-134.9
Net Profit to S'holders	1.8	1.3	41.7	2.3	2.9	-19.5
Dividends	0.0	3.5	na	0.0	3.5	na
EPS (sen)	0.5	0.4	41.7	0.7	0.8	-19.5
DPS (sen)	0.0	1.0	na	0.0	1.0	na
Operating Margin (%)	2.2	8.0	-73.1	3.0	7.0	-56.6
Net Margin (%)	4.1	3.2		2.5	3.6	na
Effective Tax rates (%)	0.5	-0.5		na	14.5	na
NTA/share (RM)				0.21	0.21	4.4

Comments
2Q YTD FY13 Revenue increased by 15% over YTD 2Q FY12. However conditions in the US remain challenging and operating margins will range between 1-5% over the next few quarters.
Net Margins will remain very thin for next few quarters.

COMPETITOR'S METRICS (All figures in MYR mn unless otherwise indicated)

Current FY Ending*	Genetec Technology Bhd Mar-13	Notion Vtec Bhd Dec-12	Dufu Technolog y Corp Bhd Dec-12
Revenue	171.6	293.0	125.0
Net Profit	3.1	40.7	4.2
Owners' Equity	75.2	305.2	90.5
Dividends	1.0	3.9	0.5
Market Cap	59.8	264.6	31.2
P-S (x)	0.3	0.9	0.2
P-E (x)	19.2	6.5	7.4
P-BV (x)	0.8	0.9	0.3
Div Yield (%)	1.7	1.5	1.6
Net Margins (%)	1.8	13.9	3.4
ROE (%)	4.1	13.3	4.6
Payout Ratio (%)	32.1	9.6	11.9

*Consensus data used for peers where available

MALAYSIA EQUITY
GENETEC TECHNOLOGY BHD**PROFIT & LOSS (All figures in MYR mn unless otherwise indicated)**

FY Mar	2011	2012	2013F	2014F
Revenue	123.0	155.4	171.6	186.6
Operating Profit	19.6	9.6	5.6	7.4
Other Income	0.2	0.1	0.3	0.8
Share of Associates	0.0	0.1	0.0	0.0
Depreciation/Amortization	-1.8	-2.1	-1.0	-1.6
Finance Costs	-1.1	-2.8	-3.3	-3.4
Pre Tax Profit	18.3	7.2	3.5	4.0
Tax	-3.2	1.6	-0.4	-0.6
Minority Interest	2.7	4.8	0.0	0.6
Net Profit to Shareholders	12.4	4.0	3.1	2.8
Operating Margin (%)	15.9	6.2	3.2	4.0
PBT Margin (%)	14.9	4.6	2.0	2.1
Net Margin (%)	10.1	2.6	1.8	1.5
Effective Tax Rate (%)	17.2	-22.6	10.4	15.0


BALANCE SHEET (All figures in MYR mn unless otherwise indicated)

FY Mar	2011	2012	2013F	2014F
Total Assets	126.9	169.8	189.4	194.8
Fixed Assets	28.4	43.0	50.3	53.0
Current Assets	72.5	88.0	99.2	99.9
Other LT Assets	26.0	38.8	39.8	42.0
Current Liabilities	36.1	66.2	83.4	86.8
LT Liabilities	9.3	20.6	23.7	25.0
Total Liabilities	45.4	86.8	107.1	111.8
Share Capital	35.2	35.2	35.2	35.2
Minority Interest	8.6	10.1	7.0	7.0
Owners' Equity	72.9	72.9	75.2	76.0
Total Equity	81.5	83.0	82.2	83.0
Total Liabilities & Equity	126.9	169.8	189.4	194.8


PER SHARE DATA (All figures in sen unless otherwise indicated)

FY Mar	2011	2012	2013F	2014F
Revenue	35.0	44.2	48.8	53.1
Cash Flow	3.0	0.6	0.6	0.3
Earnings	3.5	1.2	0.9	0.8
Dividends	0.0	1.0	0.3	0.6
Book Value	20.7	20.7	21.4	21.6
Payout (%)	0.0	86.9	32.1	71.6
P-S (x)	0.7	0.5	0.3	0.3
P-CF (x)	8.5	38.9	na	50.0
P-E (x)	7.2	18.7	19.2	21.4
P-BV (x)	1.2	1.0	0.8	0.8
Dividend Yield (%)	0.0	4.7	1.7	3.3
ROE (%)	17.0	5.6	4.1	3.7
Total Debt/Equity (%)	62.2	119.1	142.5	147.1


REVENUE - QUARTERLY LAST 7 YEARS (MYR mn)




NET PROFIT - Q'TERLY LAST 7 YRS (MYR mn)



SHARE PRICE - MONTHLY LAST 7 YEARS (MYR)



P-BV (X) - MONTHLY LAST 7 YEARS



RECENT COMPANY NEWS

ANALYST'S RECOMMENDATION RECORD

Ticker	Date	Recommendation	FairValue	Price At Date of Recommendation	% Price Change Since Prior Recommendation
GENE MK Equity	22-Feb-11	BUY	0.38	0.26	
GENE MK Equity	27-Apr-11	BUY	0.38	0.25	-5.8%
GENE MK Equity	24-May-11	BUY	0.34	0.25	2.0%
GENE MK Equity	18-Aug-11	BUY	0.34	0.25	-2.0%
GENE MK Equity	22-Nov-11	BUY	0.29	0.20	-18.4%
GENE MK Equity	22-Feb-12	HOLD	0.23	0.21	5.0%
GENE MK Equity	24-May-12	BUY	0.26	0.21	0.0%
GENE MK Equity	15-Aug-12	HOLD	0.23	0.21	0.0%
GENE MK Equity	22-Nov-12	HOLD	0.20	0.17	-19.0%
Return Since Inception					-38.1%

ANALYST'S DISCLOSURE

BUY: Share price may exceed 10% over the next 12 months

TRADING BUY: Share price may exceed 15% over the next 3 months, however longer-term outlook remains uncertain

HOLD: Share price may fall within the range of +/- 10% over the next 12 months

TAKE PROFIT: Target price has been attained. Look to accumulate at lower levels

SELL: Share price may fall by more than 10% over the next 12 months

NOT RATED (NR): Stock is not within regular research coverage

All research is based on materials compiled from data considered to be reliable at the time of writing. However, information and opinions expressed are subject to change at short notice, and no part of this report is to be construed as an offer or solicitation of an offer to transact any securities or financial instruments whether referred to herein or otherwise.

We do not accept any liability directly or indirectly that may arise from investment decision-making based on this report. The company, its directors, officers, employees and/or connected persons may periodically hold an interest and/or underwriting commitments in the securities mentioned.

This report has been prepared Wilson & York Global Advisers Sdn Bhd for purposes of CMDF-Bursa Research Scheme ("CBRS") administered by Bursa Malaysia Berhad and has been compensated to undertake the scheme. Wilson & York Global Advisers Sdn Bhd has produced this report independent of any influence from CBRS or the subject company. For more information about CBRS and other research reports, please visit Bursa Malaysia's website at: http://www.bursamalaysia.com/website/bm/listed_companies/cmdf_bursa_research_scheme/

All Rights Reserved. No part of this publication may be used or re-produced without expressed permission from Wilson & York Global Advisers Sdn Bhd.

J Charles Wilson
Head of Research

QUESTIONS?**CONTACT THE INVESTMENT ADVISER:**

Wilson & York Global Advisers Sdn Bhd
Suite B-11-3A, Level 11, Block B, Plaza Mont' Kiara
2, Jalan Kiara, Mont' Kiara
50480 Kuala Lumpur
Malaysia

Tel: +603 6203 2280
Fax: +603 6203 2281

E-mail info@wygainvestments.com
Website: www.wygainvestments.com

CONTACT THE COMPANY:

Genetec Technology Berhad
Lot 7, Jalan P10/11
Kawasan Perusahaan Bangi
43650 Bandar Baru Bangi
Selangor Darul Ehsan
Malaysia

Tel: +603 8926 6388
Fax: +603 8926 9689

Website: www.genetec.net